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Antimicrobial resistance (AMR) in Neisseria gonor-rhoeae is a global concern and affects all classes 
of antimicrobial drugs used for treatment. Penicillin, 
ciprofloxacin, and cefixime were the recommended 
first-line antimicrobial drug therapies until AMR 
prevalence breached the World Health Organiza-
tion (WHO) recommended threshold of >5% of lo-
cal isolates demonstrating resistance; at that point, 
ceftriaxone became the preferred antimicrobial drug 
treatment (1). However, ceftriaxone resistance has 
been reported in many countries and frequently in 
East and Southeast Asia, probably because of poor 
antimicrobial stewardship (2). Ceftriaxone resistance 
has been linked to mutations in the penA gene, which 
has been reported in several continents, including 
North America and Europe (3–5).
To clarify the spread of AMR in N. gonorrhoeae 
and the population groups most at risk, surveillance 
programs and research studies often link phenotypic 
susceptibility data with data on the epidemiologic 
characteristics of cases (6,7). However, these analy-
ses are limited because isolates with identical pheno-
types might not be genetically related. Consequently, 
determining the extent to which AMR transmission is 
due to clonal dissemination or separate introductions 
is challenging and these data are essential to guide 
the public health response. 
Combining phenotypic and genomic data can 
help resolve uncertainties. Whole-genome sequenc-
ing (WGS) enables investigation of genetic determi-
nants for AMR and how these are distributed in the 
pathogen population (4,5). WGS also can contribute 
evidence toward the development of rapid antimi-
crobial susceptibility tests to improve treatment deci-
sions (8,9). However, few N. gonorrhoeae WGS studies 
have been conducted in England, and none include 
representative geographic coverage over time (10–13).
We investigated the genomic and phenotypic 
variability in N. gonorrhoeae antimicrobial susceptibil-
ity in England. We described the epidemiologic char-
acteristics of genetically distinct clusters of infection 
with reduced susceptibility to cefixime, ceftriaxone, 
and azithromycin and resistance to ciprofloxacin and 
penicillin. We focused on N. gonorrhoeae with muta-
tions in the penA allele, which contribute to reduced 
susceptibility to ceftriaxone. In addition, we assessed 
the genetic similarity of N. gonorrhoeae in England, 
Europe, and the United States to determine the 
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Antimicrobial resistance (AMR) in Neisseria gonorrhoeae 
is a global concern. Phylogenetic analyses resolve un-
certainties regarding genetic relatedness of isolates with 
identical phenotypes and inform whether AMR is due to 
new mutations and clonal expansion or separate intro-
ductions by importation. We sequenced 1,277 isolates 
with associated epidemiologic and antimicrobial suscep-
tibility data collected during 2013–2016 to investigate N. 
gonorrhoeae  genomic variability in England. Comparing 
genetic markers and phenotypes for AMR, we identified 2 
N. gonorrhoeae lineages with different antimicrobial sus-
ceptibility profiles and 3 clusters with elevated MICs for 
ceftriaxone, varying mutations in the penA allele, and dif-
ferent epidemiologic characteristics. Our results indicate 
N. gonorrhoeae with reduced antimicrobial susceptibility 
emerged independently and multiple times in different 
sexual networks in England, through new mutation or re-
combination events and by importation. Monitoring and 
control for AMR in N. gonorrhoeae should cover the en-
tire population affected, rather than focusing on specific 
risk groups or locations.
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extent to which international travel might influence 
the spread of AMR in N. gonorrhoeae.
Methods
Isolate Selection
We selected N. gonorrhoeae isolates from the archives 
of the Gonococcal Resistance to Antimicrobials Sur-
veillance Programme (GRASP), a sentinel program 
implemented by Public Health England (PHE) in 
2000. GRASP is designed to represent the gonococ-
cal population in England (14) and includes clinical, 
sociodemographic, and behavioral data collected 
through the GUMCAD STI Surveillance System 
(https://www.gov.uk/guidance/gumcad-sti-sur-
veillance-system) and directly from clinics. During 
a 3-month period each year, GRASP tests for anti-
microbial susceptibility in consecutive isolates from 
all culture-positive N. gonorrhoeae cases identified in 
26 sexual health clinics in England and Wales (15). 
GRASP collects ≈1,200–2,500 isolates annually for an-
timicrobial susceptibility testing (16). 
We selected isolates collected from 5 GRASP 
clinics, 2 in London and 3 in other geographically 
distinct areas in England: Birmingham, Bristol, and 
Liverpool. We chose these locations to obtain isolates 
from cases representing a broad range of sociode-
mographic and behavioral characteristics, including 
sex, sexual orientation, age, ethnicity, and HIV status 
(Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/26/3/19-0732-App1.pdf). We sequenced all 
isolates collected during 2013–2016 by the 5 clinics 
and stored in the GRASP archive. We chose the most 
recent years of GRASP data to investigate prevailing 
trends and patterns. We did not include isolates from 
a 2015 outbreak of high-level azithromycin-resistant 
N. gonorrhoeae in the United Kingdom in this sam-
pling frame because the isolates did not meet the eli-
gibility criteria of our study. 
Ethics Considerations
PHE has permission to process confidential patient 
data obtained by GRASP under Regulation 3 (Control 
of Patient Information) of the Health Service Regula-
tions 2002. Information governance advice and ethics 
approval for this study were granted by the PHE Re-
search Ethics and Governance Group.
Antimicrobial Susceptibility Testing
GRASP tests isolates for antimicrobial susceptibility 
by using agar dilution methods, records MICs for 
antimicrobial drugs, and defines AMR by using Eu-
ropean Committee on Antimicrobial Susceptibility 
Testing (EUCAST) breakpoints. For our study, we 
used data on MICs for ceftriaxone, azithromycin, ce-
fixime, penicillin, and ciprofloxacin (17). In GRASP, 
epidemiologic data were linked to MICs for antimi-
crobial drugs for each isolate phenotype.
Isolation and WGS
We retrieved selected isolates from the GRASP ar-
chive by culturing on nonselective gonococcus agar 
(Difco BBL GC II Agar Base [Becton, Dickinson and 
Company, https://www.bd.com] plus 1% Vitox 
[Oxoid, http://www.oxoid.com]). We extracted 
DNA from a subculture of a single colony of each 
isolate by using the automated QIAsymphony DNA 
Mini Kit (QIAGEN, https://www.qiagen.com). 
WGS was conducted at the Wellcome Sanger Insti-
tute (Cambridge, UK) by using the HiSeq X Ten sys-
tem (Illumina, https://www.illumina.com) and pro-
cessed in the routine Sanger WGS data management 
pipeline (Appendix).
Data Sources from Europe and the United States
We compared the study sample with published WGS 
and associated metadata for N. gonorrhoeae isolates 
from international studies. The collection from Eu-
rope (European Nucleotide Archive (ENA; acces-
sion no. PRJEB9227) contained 1,054 isolates from 
the European Gonococcal Antimicrobial Surveillance 
Programme (Euro-GASP) (5). Isolates were collected 
in 2013 from 20 countries and included 106 isolates 
from England. We excluded 21% (22/106) that were 
duplicates of isolates in the study sample, leaving 948 
isolates from Europe. The metadata for isolates from 
Europe included reporting country, antimicrobial sus-
ceptibility profile, MICs for ceftriaxone and cefixime, 
and the presence of the penA-34 allele. We grouped 
MICs to match the categories used in GRASP. 
Isolates from the United States were from 2 pre-
vious studies investigating the association between 
phenotype and genotype for AMR in N. gonorrhoeae 
(4,9). The collection from the United States contained 
1,114 isolates collected during 2000–2013 (ENA ac-
cession nos. PRJEB2999 and PRJEB7904). The meta-
data for the isolates from the United States included 
antimicrobial susceptibility profiles; 270 had reduced 
susceptibility to cephalosporin (MIC >0.25 mg/L for 
cefixime or MIC >0.125 mg/L for ceftriaxone); 294 
had reduced susceptibility to azithromycin (MIC >2 
mg/L); and 594 were ciprofloxacin-resistant (MIC 
>1 mg/L). Metadata also included sexual orienta-
tion of case-patients and the presence of the penA-
34 allele. We grouped MICs to match the categories 
used in GRASP.
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Phylogenetic Analysis
We created phylogenetic trees and removed genetic 
recombination events by using default settings in 
Gubbins version 2.4.0 (18), including 5 iterations and 
>3 base substitutions to identify a recombination 
event, and the RAxML (Geneious, https://www.
geneious.com) or FastTree (19) tree building option 
(Appendix). We created 3 phylogenetic trees: isolates 
from England only, isolates from England and other 
countries in Europe, and isolates from England and 
the United States.
We identified known genetic markers of AMR, 
including mutations in the penA allele, by using ARI-
BA (20). We compared MICs to the genetic markers 
by using the ARIBA micplot module.
We identified the genotype of isolates in large 
and distinct clusters of N. gonorrhoeae with elevated 
MICs for ceftriaxone (MIC ≥0.015 mg/L) and cefixime 
(MIC ≥0.03 mg/L) from the phylogenetic trees. We 
compared the epidemiologic characteristics of cases 
in the clusters by using the χ2 or Fisher exact test.
Statistical Analysis
We used univariate and multivariable analyses to as-
sess differences in the epidemiologic characteristics 
and antimicrobial susceptibility of isolates between lin-
eages identified in the phylogenetic tree. We analyzed 
the following explanatory variables: year and location 
the isolate was collected; case-patient information, 
including gender, sexual orientation, age, ethnicity, 
country of birth, whether they had a symptomatic N. 
gonorrhoeae infection or previous sexually transmitted 
infection (STI), HIV status, and the number of sexual 
partners they had in the United Kingdom or through 
travel-associated sexual partnerships <3 months be-
fore diagnosis; and isolate susceptibility data, includ-
ing reduced susceptibility to ceftriaxone (MIC >0.015 
mg/L), cefixime (MIC >0.03 mg/L), or azithromycin 
(MIC >0.25 mg/L); or resistance to penicillin (MIC >1 
mg/L or β-lactamase positive) or ciprofloxacin (MIC 
>0.06 mg/L). We used elevated MIC thresholds for 
ceftriaxone, cefixime, and azithromycin to provide a 
robust sample size for regression analysis. 
We also explored the relationship between travel-
associated sexual partnerships and reduced suscepti-
bility to antimicrobial drugs by conducting univariate 
and multivariable analyses with reduced susceptibil-
ity or resistance as the outcome and travel-associated 
sexual partnerships as the primary explanatory vari-
able. We considered CI of the odds ratio (OR) >1.0 
and p<0.05 by χ2 test as statistically significant. 
We developed multivariable logistic regression 
models by using a forward approach and including 
only statistically significant variables associated 
with the outcome in the univariate model to con-
trol for possible confounding between variables. We 
used the likelihood ratio test to determine which 
explanatory variables should remain in the multi-




Of the eligible isolates, we successfully sequenced 
91% (1,277/1,407); the bacteria of the remaining 130 
isolates were no longer viable for DNA extraction. For 
all antimicrobial drugs tested, the MIC distributions of 
the study isolates were similar to those of all GRASP 
isolates (Appendix Table 2). We found that 3.6% of iso-
lates were resistant to azithromycin (MIC >0.5 mg/L) 
and 2 isolates were highly resistant (MIC >256 mg/L); 
0.6% were resistant to cefixime (MIC >0.125 mg/L), 
36.3% to ciprofloxacin (MIC >0.06 mg/L), 16.6% to 
penicillin (MIC >1 mg/L), and none to ceftriaxone 
(MIC >0.125 mg/L). The MIC distribution of the iso-
lates not sequenced was similar to the distribution of 
the sequenced isolates. Most (69%; 881/1,277) isolates 
were from genital infections, 23.4% (299/1,277) were 
from rectal infections, and 6.3% (80/1,277) were from 
pharyngeal infections. Overall, we identified 226 dif-
ferent sequence types (STs) by using N. gonorrhoeae 
multiantigen sequence typing (NG-MAST) (Appen-
dix). We deposited novel sequences extracted for this 
study into ENA (accession no. ERP022090) and pro-
vide metadata (Appendix).
N. gonorrhoeae Lineages Circulating in England
We noted 2 distinct lineages in the phylogenetic tree 
(Figure 1). Compared with lineage B, lineage A was 
more likely to contain isolates from clinics in London 
than those outside of London (outside London:in 
London adjusted odds ratio [aOR] 1.74, 95% CI 1.27–
2.67; p = 0.001). Lineage A also contained more iso-
lates from persons >35 years of age than persons <24 
years of age (aOR 1.68, 95% CI 1.16–2.40; p = 0.006). 
Asian ethnicity also was associated more frequently 
with isolates from lineage A compared with white 
ethnicity (aOR 1.86, 95% CI 1.01–3.45; p = 0.048) (Ta-
ble 1). Lineage A was less likely to contain isolates 
from women (aOR 0.14, 95% CI 0.09–0.22; p<0.001) 
or men who reported having sex with women exclu-
sively (MSW; aOR 0.33, 95% CI 0.23–0.47; p<0.001) 
compared with MSM. This lineage also was less likely 
to contain isolates from persons reporting black Ca-
ribbean ethnicity compared with persons reporting 
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white ethnicity (aOR 0.49, 95% CI 0.32–0.76; p = 
0.001). Lineage A was more likely to contain isolates 
from persons who reported a travel-associated sexual 
partnership compared with isolates from lineage B 
(crude odds ratio [cOR] 1.96, 95% CI 1.20–3.21; p = 
0.006), but this association did not persist in the mul-
tivariable model (aOR 1.66, 95% CI 0.94–2.91; p = 
0.078 adjusting for location, age, sex, sexual orienta-
tion, and ethnicity). However, isolates from persons 
who had a recent travel-associated sexual partnership 
were more likely to be resistant to ciprofloxacin (aOR 
1.83, 95% CI 1.13–2.96; p = 0.015, adjusting for loca-
tion, age, sex, sexual orientation, and ethnicity). We 
saw no statistically significant association between 
recent travel-associated sexual partnerships and N. 
gonorrhoeae with reduced susceptibility to ceftriaxone, 
cefixime, or azithromycin, or resistance to penicillin.
Isolates with reduced susceptibility to ceftriax-
one, cefixime, or azithromycin or resistance to cip-
rofloxacin and penicillin were dispersed throughout 
the phylogenetic tree (Figure 1). However, compared 
with lineage B, isolates in lineage A were more likely 
to have higher MICs for ceftriaxone (aOR 15.4, 95% 
CI 8.50–27.8; p<0.001), cefixime (aOR 3.97, 95% CI 
2.76–5.76; p<0.001), azithromycin (aOR 7.5, 95% CI 
5.37–10.5; p<0.001), and penicillin (aOR 18.2, 95% CI 
11.4–29.2; p<0.001) (Table 2).
Distribution of penA Alleles across the Phylogeny
Overall, we identified 32 different known mutations 
in 8 genes associated with resistance to ceftriaxone, 
cefixime, azithromycin, ciprofloxacin, or penicil-
lin. For all antimicrobial drugs, we noted isolates 
with the same combination of genotypic markers of 
Figure 1. Phylogeny and antimicrobial susceptibility of Neisseria gonorrhoeae isolates from England, 2013–2016.  Maximum-likelihood 
phylogeny with recombination events removed of all N. gonorrhoeae isolates annotated with gender and sexual orientation, antimicrobial 
susceptibility phenotype, and penA genotype. Asterisks represent location in tree of isolates with high-level azithromycin resistance (MIC 
>256 mg/L). Heterosexual men were those who reported sex with women exclusively.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 3, March 2020 509
N. gonorrhoeae Antimicrobial Susceptibility
resistance but differing phenotypic MICs (Appendix 
Figures 1–5).
The larger, distinct clusters with elevated MICs for 
ceftriaxone and cefixime contained the penA-34 allele 
and the penA-44 allele (Figure 1). All isolates with the 
penA-34 allele (n = 86) had a MIC of >0.015 mg/L for 
cefixime and 67 had a MIC of >0.015 mg/L for ceftriax-
one. Most (81/84; 96%) isolates with the penA-44 allele 
had a MIC of >0.015 mg/L for cefixime, a MIC of >0.015 
mg/L for ceftriaxone (83/84; 98%), or both (81/84; 96%). 
The 2 largest clusters with the penA-34 allele 
(cluster 1, n = 57; cluster 2, n = 26) were genetically 
distinct from each other and isolates in the 2 groups 
had statistically significant differences by year, clinic, 
sexual orientation, and HIV status (Table 3). Most 
(81%; 21/26) isolates in cluster 2 were from London 
in 2014–2015, and most (67%; 38/57) in cluster 1 were 
from outside London but distributed across all 4 years 
of the study. Most (96%; 25/26) isolates in cluster 2 
were from MSM; whereas cluster 1 was more mixed 
and composed of isolates from women (21%; 12/57), 
MSW (37%; 21/57), and MSM (42%; 24/57). Cluster 2 
had a higher percentage of persons living with HIV 
(35%; 9/26) than did cluster 1 (7%; 4/57). Most (82%; 
 
Table 1. Univariate and multivariable analyses comparing the epidemiologic characteristics of cases of Neisseria gonorrhoeae 








A B cOR 95% CI p value aOR 95% CI p value 
Total 838 439   
Year 
 2013 220 106  Ref    
 
 2014 210 123  0.82 0.60–1.13 0.234  
 2015 260 107  1.17 0.85–1.62 0.339  
 2016 148 103  0.69 0.49–0.98 0.035  
Clinic location 
 Outside London 630 136  Ref    Ref   
 London 463 109  3.73 2.86–4.88 <0.001  1.74 1.27–2.67 0.001 
Sex and sexual orientation 
 MSM 630 136  Ref    Ref   
 MSW 150 154  0.21 0.15–0.29 <0.001  0.33 0.23–0.47 <0.001 
 F 57 149  0.08 0.05–0.12 <0.001  0.14 0.09–0.22 <0.001 
Age, y 
 ≤24 188 196  Ref    Ref   
 25–34 342 161  2.21 1.67–2.93 <0.001  1.14 0.83–1.59 0.413 
 ≥35 308 82  3.92 2.81–5.46 <0.001  1.68 1.16–2.40 0.006 
Ethnicity 
 White 586 238  Ref    Ref   
 Black Caribbean 51 81  0.26 0.17–0.38 <0.001  0.49 0.32–0.76 0.001 
 Black African 27 20  0.55 0.30–1.00 0.046  0.84 0.43–1.64 0.607 
 Black Other 6 4  0.61 0.17–2.18 0.442  0.57 0.14–2.37 0.441 
 Asian 57 17  1.36 0.78–2.39 0.280  1.86 1.01–3.45 0.048 
 Other 24 8  1.22 0.54–2.75 0.634  0.99 0.41–2.44 0.999 
 Mixed 62 43  0.59 0.39–0.89 0.011  0.82 0.51–1.32 0.413 
Place of birth 
 United Kingdom 473 309  Ref    
 
 Not United Kingdom 305 102  1.95 1.49–2.56 <0.001  
Symptomatic infection 
 No 219 119  Ref    
 
 Yes 526 277  1.03 0.79–1.35 0.818  
New STI diagnosis <1 year, excluding HIV 
 No or unknown 615 363  Ref    
 
 Yes 223 75  1.75 1.31–2.35 <0.001  
HIV status 
 Negative or unknown 653 398  Ref    
 
 Positive 185 41  2.75 1.91–3.96 <0.001  
Number of partners in the United Kingdom <3 months of diagnosis 
 0 27 20  Ref    
 
 1 175 162  0.80 0.43–1.48 0.478  
 ≥2 304 167  1.35 0.73–2.48 0.335  
Travel-associated sexual partnerships <3 months of diagnosis 
 No 442 325  Ref    
 
 Yes 64 24  1.96 1.20–3.21 0.006  
*The multivariable model was adjusted for location, gender and sexual orientation, age, and ethnicity. Bold text indicates statistical significance (p<0.05 
and 95% CI does not cross 1.0). aOR, adjusted odds ratio; cOR, crude odds ratio; MSM, men who have sex with men; MSW, men who reported sexual 
activity exclusively with women; Ref, referent; STI, sexually transmitted infection.  
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69/84) isolates with the penA-44 allele were from 
MSM, persisted over all 4 years of the study, and 
were found both inside and outside of London. The 
characteristics of isolates with the penA-44 allele were 
more similar to the characteristics of isolates in clus-
ter 2 of the penA-34 group than to isolates in cluster 1 
(Appendix Table 3).
Comparison of Isolates from England, Europe,  
and the United States
Isolates from England were genetically interspersed 
with isolates from other countries in Europe (Fig-
ure 2) or the United States (Figure 3), although some 
large clades of isolates came only from England or the 
United States. Isolates in cluster 1 with the penA-34 
allele in England were clustered with isolates from 
Europe and the United States (Figures 2–3). Isolates 
with the penA-34 allele in cluster 2 from England that 
were only found after 2013 were not related geneti-
cally to isolates from the United States or from other 
countries in Europe.
Discussion
We conducted a large study on genomic variability of 
antimicrobial susceptibility in N. gonorrhoeae in Eng-
land. We sampled isolates from geographically dis-
persed clinics in England, and our data likely repre-
sent patterns at a national level. Our data suggest that 
N. gonorrhoeae with reduced susceptibility to antimi-
crobial drugs, including ceftriaxone, has emerged in 
England through novel mutation and recombination 
events, repeated introduction from overseas, clonal 
expansion, or a combination of these. 
We observed 3 distinct clusters with 2 different 
penA alleles and reduced susceptibility to ceftriaxone 
and cefixime and found patients in each cluster with 
differing epidemiologic characteristics. The genetic 
similarity of isolates from England, Europe, and the 
United States is consistent with global dissemination 
of N. gonorrhoeae concerning genotypic and pheno-
typic features. Our data highlight the potential in-
fluence of travel-associated sexual partnerships in 
AMR transmission.
As seen in other N. gonorrhoeae studies, the high 
frequency of DNA recombination requires compu-
tational strategies to use single-nucleotide polymor-
phism differences arising through mutation rather 
than recombination. We identified and removed re-
combinant DNA, but some likely remained, which 
might lead to incorrect inferences about relatedness 
for some isolates.
We found 2 distinct lineages of N. gonorrhoeae 
with different antimicrobial susceptibility profiles 
circulating in England. The larger lineage contained 
isolates with elevated MICs or resistance to all 5 an-
timicrobial drugs tested, consistent with findings 
from recent studies in Europe and globally (5,21). The 
authors of those studies hypothesized that differing 
susceptibility profiles of the 2 lineages were associ-
ated with different sexual orientation networks, but 
neither study had complete data on sexual orienta-
tion to support the hypothesis. Our study includes 
sexual orientation data for 99% of cases. Our findings 
strongly support the hypothesis that MSM are more 
frequently infected with N. gonorrhoeae strains with 
reduced susceptibility to antimicrobials, whereas 
MSW and women are more frequently infected with 
the more susceptible lineage. Nevertheless, many 
MSW were infected with N. gonorrhoeae with reduced 
susceptibility to antimicrobial drugs and MSM were 
 
Table 2. Association between antimicrobial susceptibility of Neisseria gonorrhoeae isolates and presence in lineage A of the 
phylogeny, England* 
Susceptibility Lineage A, no. isolates Lineage B, no. isolates aOR 95% CI p value 
Reduced  
 Ceftriaxone, MIC ≥0.015 mg/L 
  No 572 418 Referent – – 
  Yes 263 15 15.4 8.50–27.8 <0.001 
 Cefixime, MIC ≥0.03 mg/L 
  No 544 370 Referent – – 
  Yes 291 63 3.97 2.76–5.76 <0.001 
 Azithromycin, MIC ≥0.25 mg/L 
  No 328 367 Referent – – 
  Yes 507 66 7.50 5.37–10.5 <0.001 
Resistant  
 Penicillin, MIC >1 mg/L or β-lactamase positive 
  No 671 378 Referent – – 
  Yes 164 55 1.33 0.92–1.93 0.134 
 Ciprofloxacin, MIC >0.06 mg/L 
  No 400 408 Referent – – 
  Yes 435 25 18.2 11.4–29.2 <0.001 
*Each model adjusted for location inside or outside of London, and patient age, sexual orientation, and ethnicity. Nine isolates did not have MIC data. 
Bold text indicates statistical significance, i.e., p<0.05 and 95% CI does not cross 1. aOR, adjusted odds ratio. 
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infected by antimicrobial-susceptible N. gonorrhoeae, 
and we noted intralineage variation by sexual orien-
tation. MSM have more bacterial STI diagnoses and 
greater exposure to antimicrobial drugs, thereby in-
creasing selection pressures for AMR, a hypothesis 
supported by mathematical models (21–24). Resistant 
strains also might persist in the absence of selective 
pressure because the organism’s biologic fitness is 
unaffected or compensatory mutations mitigate a del-
eterious effect (25–27).
By combining WGS, epidemiologic, and phe-
notypic data, we found that reduced susceptibility 
to ceftriaxone and cefixime emerged repeatedly in 
separate sexual networks in England. Without WGS 
data, we would have grouped all penA-34 samples 
from MSM together. Likewise, if we restricted se-
quencing to the penA gene, we would not have identi-
fied unique clusters with the same penA-34 allele.
The large group of isolates in England with the 
penA-34 allele clustered with isolates from Europe 
and the United States that had the same allele. Some 
of the penA-34 allele isolates belonged to the NG-
MAST 1407 lineage, a widely disseminated clone as-
sociated with elevated MICs for ceftriaxone and cefix-
ime and the catalyst for changing national treatment 
guidelines in the United Kingdom from cefixime as 
 
Table 3. Epidemiologic characteristics of patients from whom Neisseria gonorrhoeae isolates were collected in the 2 largest penA-34 
clusters, England* 
Characteristics Total Cluster 1, n = 57, no. (%) Cluster 2, n = 26, no. (%) p value† 
Year 
 2013 26 26 (45.6) 0 <0.001‡ 
 2014 29 14 (24.6) 15 (57.7) 
 2015 20 10 (17.5) 10 (38.5) 
 2016 8 7 (12.3) 1 (3.8) 
Sex and sexual orientation 
 MSM 49 24 (42.1) 25 (96.2) <0.001‡ 
 MSW 21 21 (36.8) 0 
 F 13 12 (21.1) 1 (3.8) 
Clinic location 
 Outside London 43 38 (66.7) 5 (19.2) <0.001‡ 
 London 40 19 (33.3) 21 (80.8) 
Age, y 
 ≤24 28 23 (40.4) 5 (19.2) 0.081 
 25–34 29 20 (35.1) 9 (34.6) 
 ≥35 26 14 (24.6) 12 (46.2) 
Ethnicity 
 White 59 37 (68.5) 22 (84.6) 0.408‡ 
 Black Caribbean 6 6 (11.1) 0 
 Black, Other 2 2 (3.7) 0 
 Asian 5 4 (7.4) 1 (3.8) 
 Other 4 2 (3.7) 2 (7.7) 
 Mixed 4 3 (5.6) 1 (3.8) 
Place of birth 
 United Kingdom 40 30 (52.6) 10 (38.5) 0.262‡ 
 Not United Kingdom 40 26 (45.6) 14 (53.9) 
 Unknown 3 1 (1.7) 2 (7.7) 
Symptomatic infection 
 No 28 13 (24.5) 15 (57.7) 0.004 
 Yes 51 40 (75.5) 11 (42.3) 
New STI diagnosed <1 year, excluding HIV 
 No 68 51 (89.5) 17 (65.4) 0.013‡ 
 Yes 15 6 (10.5) 9 (34.6) 
HIV status 
 Negative or unknown 70 53 (93.0) 17 (65.4) 0.003‡ 
 Positive 13 4 (7.0) 9 (34.6) 
Number of sexual partners in the United Kingdom <3 mo of N. gonorrhea diagnosis 
 0 6 6 (13.3) 0 0.675‡ 
 1 19 16 (35.6) 3 (33.3) 
 ≥2 29 23 (51.1) 6 (66.7) 
Travel-associated sexual partnership 
 No 43 34 (75.6) 9 (100) 0.178‡ 
 Yes 11 11 (24.4) 0 
*Bold text indicates statistical significance (i.e., p<0.05 and 95% CI does not cross 1). MSM, men who have sex with men; MSW, men who reported 
sexual activity exclusively with women. 
†Calculated using χ2 test, except where noted.  
‡Calculated using Fisher exact test.  
 
RESEARCH
512 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 3, March 2020
first-line therapy to ceftriaxone in 2011 (6,22). There-
fore, the larger penA-34 group probably represents 
clonal spread of a previously identified endemic 
strain of N. gonorrhoeae; the smaller penA-34 group 
represents a new strain emerging in a different sexual 
network largely comprising MSM in London with 
a history of STIs, including HIV. Consequently, re-
stricting public health resources that measure, pre-
vent, and control AMR in N. gonorrhoeae to specific 
risk groups or geographic locations could be ineffec-
tive because AMR appears to emerge independently 
in different sexual networks and locations.
We found some evidence for importation of 
AMR. Isolates from persons who recently had a trav-
el-associated sexual partnership were more likely 
to be infected with N. gonorrhoeae that was resistant 
to ciprofloxacin. Although de novo development of 
high-level resistance to azithromycin in the United 
Kingdom has been described, some studies have 
concluded that importation events probably initiate 
AMR spread in countries with low population preva-
lence, such as England (11,27,28). The success of anti-
microbial stewardship policies and compliance with 
treatment guidelines that aim to curtail AMR in the 
endemic gonococcal population in England could 
be undermined by the importation and subsequent 
spread of resistant isolates. These data support the 
importance of promoting STI prevention messages 
and testing to international travelers, particularly 
those visiting countries where AMR N. gonorrhoeae 
is endemic. Quantifying the relationship between 
N. gonorrhoeae circulating in England and interna-
tionally also could help parameterize mathematical 
models exploring the relative contribution of impor-
tation and de novo development on AMR prevalence 
and distribution.
Rapid molecular tests for genetic markers that 
are highly predictive of an antimicrobial susceptibil-
ity phenotype could lead to more effective use of an-
timicrobials. Tests detecting markers of ciprofloxacin 
and cephalosporin antimicrobial susceptibility are 
already in development (8,29,30). However, as found 
in our study and elsewhere, the association between 
genotype and phenotype is much stronger for cipro-
floxacin resistance than for cephalosporin resistance 
(4,31,32). Most rapid tests for cephalosporin resis-
tance focus on detecting mutations in the penA allele, 
but reduced susceptibility to cephalosporins also can 
Figure 2. Phylogenetic tree of 
Neisseria gonorrhoeae isolates 
from England and other countries 
in Europe in a study of antimicrobial 
susceptibility, 2013–2016, including 
metadata for study type, MICs 
for ceftriaxone and cefixime, and 
presence of penA-34 alleles. We 
sequenced 1,277 isolates; 948 isolates 
were from other countries in Europe. 
The penA-34 clades from Europe are 
labeled M1 and M2, as noted by  
Harris et al. (5).
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be caused by mutations in the semimosaic penA allele, 
penA-35, the nonmosaic penA allele, penA-44, or even 
in the mtrR and penB genes (30,33).
Molecular tests that focus on the presence or ab-
sence of 1 mutation without considering the additive 
effect of multiple mutations could be insufficient for 
detecting resistance and predicting treatment fail-
ure. Epistasis, in which phenotypic resistance is de-
pendent on complex interactions of multiple mutant 
genes, is known to occur in N. gonorrhoeae (22,31,34). In 
our study, the antimicrobial susceptibility of isolates 
with identical genetic markers of resistance varied by 
>2 doubling dilutions, and most isolates with resis-
tance markers were sensitive. Nonetheless, the pres-
ence of 1 mutation that belongs to a complex of mu-
tations required for resistance indicates the potential 
for phenotypic resistance to develop. Clinicians could 
prioritize patients infected with these strains for a test 
of cure or consider use of alternative antimicrobial 
drugs unaffected by the resistance marker. In any 
event, mathematical modeling studies have shown 
that molecular tests should only be implemented if 
they are highly sensitive; otherwise, they could ac-
celerate the spread of AMR (23). Elucidation of the 
mechanisms and genomic markers of cephalosporin 
resistance is needed and can be achieved through a 
combination of microbiologic and genomic studies, 
including genomewide association studies. WGS can-
not replace phenotypic testing for all antimicrobial 
susceptibility because it can only detect known muta-
tions associated with resistance, and novel mutations 
associated with resistance develop constantly in N. 
gonorrhoeae (31).
In conclusion, phylogenetic analyses with WGS 
data revealed transmission patterns of N. gonorrhoeae 
with reduced susceptibility in England that would 
not have been identified by using only epidemio-
logic and phenotypic data. Reduced susceptibility to 
Figure 3. Phylogenetic tree 
of Neisseria gonorrhoeae 
isolates from England and 
the United States in a study 
of antimicrobial susceptibility, 
2013–2016, including 
metadata for study type, MICs 
for ceftriaxone and cefixime, 
and presence of penA-34 
alleles. We sequenced 1,277 
isolates; 1,114 isolates were 
from the United States.
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antimicrobial drugs likely has emerged and spread 
independently in different sexual networks in Eng-
land through multiple de novo mutation and recom-
bination events and through some repeated impor-
tation by persons who have travel-associated sexual 
partnerships. Consequently, public health actions to 
limit dissemination of AMR in England should aim 
to reduce risk behaviors that support N. gonorrhoeae 
transmission and encompass the diffuse distribu-
tion and epidemiologic diversity of the population 
groups affected.
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